Parenteral products have become one of the most important innovation and growth drivers in the biopharma industry. But as drug developers race to meet the world’s demand for injectable products, the market they’re seeking to capture is changing just as fast.
The trend toward home-based care – which emerged pre-COVID-19 and was accelerated by the pandemic – has transformed the target profile for a high-value injectable drug. Today’s global market isn’t simply demanding more effective parenteral therapies – it’s looking for convenient, self-administered products that offer an easy, safe, adherence-supporting delivery experience.
For many organizations, this shift has put increasing focus on launching their products in an autoinjector, pen, wearable, or other delivery device. This launch can be one of the most technically-demanding pivots in the product life cycle – one that combines the unique complexities of both aseptic fill-finish and device assembly. But it’s also an increasingly vital step for drug developers who want to maximize the value of their product.
The market is eager for products that deliver not only therapeutic benefits, but also an easy, safe, adherence-supporting delivery experience.
Markus Hoerburger, Product- and Servicemanager